Progress in the field of precision medicine has changed the landscape of cancer therapy.
Precision medicine is propelled by technologies that enable molecular profiling, genomic …

Purpose This review provides an overview of the current challenges in oral targeted
antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug …

Although kinase inhibitors (KI) frequently portray large interpatient variability, a 'one size fits
all'regimen is still often used. In the meantime, relationships between exposure-response …

Purpose While in the era of precision medicine, the right drug for each patient is selected
based on molecular tumor characteristics, most novel oral targeted anticancer agents are …

Tyrosine kinase inhibitors (TKIs) are anti‐cancer drugs that target tyrosine kinases, enzymes
that are involved in multiple cellular processes. Currently, multiple oral TKIs have been …

Pazopanib is an inhibitor of the vascular endothelial growth factor receptor, platelet-derived
growth factor receptor, fibroblast growth factor receptor and stem cell receptor c-Kit, and has …

Purpose: Pazopanib is a tyrosine kinase inhibitor approved for the treatment of renal cell
carcinoma and soft tissue sarcoma. Retrospective analyses have shown that an increased …

Aim Fixed dose oral tyrosine kinase inhibitors imatinib, sunitinib and pazopanib show a high
interpatient variability in plasma exposure. A relationship between plasma exposure and …

Background Pazopanib is an angiogenesis inhibitor approved for the treatment of renal cell
carcinoma and soft tissue sarcoma. Post hoc analysis of a clinical trial demonstrated a …

Background Cabozantinib is a tyrosine kinase inhibitor with a substantial efficacy in
metastatic renal cell carcinoma, and is associated with a challenging toxicity profile leading …